The Retatrutide Phase 3 clinical programme is among the most closely followed late-stage metabolic studies in recent years. This summary reviews what the TRIUMPH and TRANSCEND trials are investigating and the headline endpoints Eli Lilly has reported, framed strictly as a review of published pharmaceutical research. Retatrutide (development code LY3437943) is a single-molecule triple agonist of the GIP, GLP-1 and glucagon receptors, and the Phase 3 data extend the metabolic findings first seen in the earlier Phase 2 work.
What the TRIUMPH programme is studying
TRIUMPH is Eli Lilly's Phase 3 development programme for retatrutide. It spans a broad set of investigational indications studied in human clinical trials: obesity and weight management, type 2 diabetes mellitus (T2DM), knee osteoarthritis associated with obesity, obstructive sleep apnoea, metabolic dysfunction-associated steatotic liver disease (MASLD), and cardiovascular outcomes. The breadth of the programme reflects the scientific interest in whether engaging three metabolic receptors at once produces effects across multiple organ systems rather than a single endpoint.
TRIUMPH-4: weight and osteoarthritis endpoints
Results from TRIUMPH-4, reported in December 2025, examined retatrutide at 9mg and 12mg doses. Alongside body-weight reduction, the trial measured WOMAC pain-score improvements in participants with knee osteoarthritis — a secondary line of inquiry into whether weight reduction and the compound's metabolic effects translate into measurable joint-pain outcomes. As with all data discussed here, these are findings from Lilly's investigational pharmaceutical trials.
TRANSCEND-T2D-1: type 2 diabetes results
TRANSCEND-T2D-1 reported Phase 3 results in June 2026 in adults with type 2 diabetes. The data were presented at the American Diabetes Association's 86th Scientific Sessions and published in The Lancet. The trial assessed glycaemic endpoints alongside body-weight change, adding type 2 diabetes evidence to the obesity-focused TRIUMPH data.
Headline efficacy figures
Across the late-stage programme, the most widely cited figure is a body-weight reduction of up to roughly -23.7% (about -27.2 kg, or around -60 lbs) at the 12mg dose. These magnitudes are larger than those reported for single-receptor GLP-1 agonists and broadly in line with — or exceeding — dual GIP/GLP-1 agonists, which is the central reason retatrutide is studied as a distinct pharmacological class.
The mechanism behind the outcomes
Retatrutide's distinguishing feature is triple agonism. GLP-1 and GIP are incretin pathways studied for their roles in insulin secretion and appetite signalling, while the glucagon-receptor component is studied for its influence on energy expenditure and hepatic lipid handling. For a deeper treatment of the receptor pharmacology, see our explainer on the retatrutide mechanism of action, and the comparison with single-agonist compounds in retatrutide vs semaglutide.
What Phase 3 completion means for the research landscape
As a compound progresses through Phase 3, the volume of well-characterised pharmacological data grows, which in turn sharpens the questions laboratory researchers ask about receptor binding, selectivity and downstream signalling. None of this changes the regulatory status of research-grade material: it remains an investigational compound, not an approved product.
The Phase 2 origins of the programme
The Phase 3 programme did not appear in isolation. It was built on a Phase 2 obesity trial whose results were presented around the 2023 American Diabetes Association Scientific Sessions and published in the New England Journal of Medicine, alongside a separate Phase 2 type 2 diabetes study reported in The Lancet. Those earlier trials established the dose range, the escalation schedule used to manage tolerability, and the headline observation that weight reductions scaled with dose. Phase 3 was designed to confirm those signals in much larger populations and across a wider set of indications, which is why the TRIUMPH programme is structured as a family of trials rather than a single study.
Organ-specific and cardiovascular arms
Beyond the headline weight and glycaemic endpoints, several TRIUMPH arms examine specific organ systems. Trials in obstructive sleep apnoea measure changes in apnoea-hypopnoea indices; liver-focused arms study markers relevant to metabolic dysfunction-associated steatotic liver disease (MASLD), including liver-fat measures; and a dedicated cardiovascular outcomes arm follows participants over a longer horizon to assess major adverse cardiovascular events. The breadth reflects a recurring research theme: a compound that alters whole-body energy metabolism may produce measurable changes in several systems at once, and each must be studied with its own validated endpoints.
How endpoints are measured
Interpreting trial figures requires understanding how they are generated. Body-weight outcomes are typically reported as percentage change from baseline at a defined timepoint, often using statistical frameworks that distinguish treatment-policy estimands (what happens to everyone assigned a dose) from efficacy estimands (what happens to those who adhere). Glycaemic endpoints centre on HbA1c change, and osteoarthritis endpoints on validated instruments such as the WOMAC pain subscale. These methodological details matter because two trials can report different numbers for reasons of analysis rather than pharmacology — a distinction researchers reading primary sources should keep in mind.
What this means for in vitro research
For laboratory researchers, the value of the Phase 3 data is contextual rather than procedural. A larger evidence base sharpens the mechanistic questions worth asking in vitro: how receptor occupancy relates to downstream signalling, how selectivity across the three receptors shapes the response, and how the compound behaves under controlled assay conditions. None of the clinical figures translate into a laboratory protocol, but they frame why the compound's receptor pharmacology is worth characterising carefully with verified material.
Research-grade retatrutide and the published data
It is important to separate two things. The clinical figures above relate to Eli Lilly's investigational pharmaceutical formulation. The HPLC-verified retatrutide supplied for laboratory research is used to study the compound's mechanisms in vitro and is not the same as any approved or investigational pharmaceutical product. Researchers sourcing material can review the Retatrutide buying guide, the peptide format overview, and the wider verified-source guidance, then check the batch Certificate of Analysis on the product page. The full library of explainers is collected on the Retatrutide research hub.